Kevin Koch
Fortune : 16 M $ au 31/08/2026
Fortune : 16 M $ au 31/08/2026
Dr. Kevin Koch is a President, Chief Executive Officer & Director at Edgewise Therapeutics, Inc. and a Venture Partner at OrbiMed Advisors Private Equity.
He is on the Board of Directors at Edgewise Therapeutics, Inc., Encycle Therapeutics, Inc., Neurogastrx, Inc. and Skyhawk Therapeutics, Inc. Dr. Koch was previously employed as an Independent Director by Miragen Therapeutics, Inc., a Senior Vice President by Biogen, Inc., a President & Chief Scientific Officer by Array BioPharma, Inc., an Associate Director-Medicinal Chemistry by Amgen, Inc., and a Senior Research Investigator by Pfizer Inc. He also served on the board at Terremoto Biosciences, Inc., Inflammation Research Association, Inc. and Ataxion, Inc. He received his undergraduate degree from Stony Brook University, a graduate degree from the University of Rochester and a doctorate degree from the University of Rochester.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/08/2026 | 391 272 ( 0,36% ) | 16 M $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Directeur Général | 01/08/2017 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Private Equity Investor | 01/05/2016 |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Directeur/Membre du Conseil | - |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Directeur/Membre du Conseil | 04/01/2018 |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. BiotechnologyHealth Technology Develops novel RNA-targeting small molecule for neurology, oncology and fibrotic diseases | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Directeur/Membre du Conseil | 01/12/2023 |
| VIRIDIAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/10/2020 |
| BIOGEN INC. | Corporate Officer/Principal | 01/09/2015 |
| ARRAY TECHNOLOGIES, INC. | Fondateur | 29/11/2013 |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 14 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes biopharmaceutical drugs | Health Technology |
Stony Brook University
Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Inflammation Research Association, Inc.
Inflammation Research Association, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in encouraging scientists, researchers, students, teachers and clinicians with an interest in inflammation biology | Commercial Services |
Ataxion, Inc.
Ataxion, Inc. BiotechnologyHealth Technology Develops novel therapies for rare, debilitating, and underserved neurologic diseases | Health Technology |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. BiotechnologyHealth Technology Develops novel RNA-targeting small molecule for neurology, oncology and fibrotic diseases | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national